BioMed Realty is proud to welcome Insmed Incorporated to its B960 building at the Babraham Research Campus in Cambridge, UK. The global biopharmaceutical company has officially opened its new 17,000 square feet R&D facility, marking a significant expansion of its UK presence and reinforcing Cambridge’s position as a leading hub for life sciences innovation.
Her Royal Highness The Princess Royal commemorated the facility’s opening with a tour led by Insmed Chair and CEO Will Lewis, and Insmed Senior Vice President of Research Tom Heightman, highlighting the importance of the scientific work being done on site to address serious diseases.
“Insmed’s presence at B960 reflects the strength of the Babraham Research Campus ecosystem and the continued demand for high-quality R&D environments in Cambridge,” said Orestis Tzortzoglou, BioMed Realty’s Head of UK Market. “Our lab and office space is designed to accelerate collaboration and discovery – and we’re proud to support Insmed’s mission to transform patient outcomes globally.”
Located within the heart of one of the UK’s most established research campuses, B960 offers advanced lab infrastructure and proximity to world-class academic and clinical institutions, making it an ideal home for pioneering biopharmaceutical work.
BioMed Realty remains committed to providing mission-critical infrastructure that helps innovative companies like Insmed thrive and grow in the UK and beyond.
